USE OF HYPOMETHYLATING AGENTS IN RELAPSED/REFRACTORY PEDIATRIC ACUTE MYELOID LEUKEMIA

被引：0
|
作者：
Sabnis, Himalee [1 ]
Raikar, Sunil [1 ]
Bennett, Anna [1 ]
MacDonald, Kelly [1 ]
Watkins, Benjamin [1 ]
Woods, William [1 ]
Keller, Frank [1 ]
机构：
[1] Childrens Healthcare Atlanta, Atlanta, GA USA
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
81
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [1] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Mei, Matthew
    Salhotra, Amandeep
    Khaled, Samer
    Nakamura, Ryotaro
    Snyder, David
    O'Donnell, Margaret
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    HAEMATOLOGICA, 2018, 103 (09) : E404 - E407
  • [2] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Pillai, Raju
    Sanchez, James F.
    Mei, Matthew
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Khaled, Samer
    Sun, Weili
    O'Donnell, Margaret
    Snyder, David
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : E253 - E255
  • [3] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
    Mohassel, Leila
    Yakubi, Hanna
    Jones, Kendra
    Wang, Hongkun
    Shafer, Danielle
    BLOOD, 2022, 140 : 6158 - 6159
  • [4] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
    Graveno, Molly E.
    Carulli, Alison
    Freyer, Craig W.
    Mangan, Brendan L.
    Nietupski, Robert
    Loren, Alison W.
    Frey, Noelle, V
    Porter, David L.
    Gill, Saar, I
    Hexner, Elizabeth O.
    Luger, Selina M.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Perl, Alexander E.
    Babushok, Daria, V
    Pratz, Keith W.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
  • [5] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Luo, Tingyue
    Yu, Sijian
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Shao, Ruoyang
    Du, Xin
    Jin, Hua
    Liu, Qifa
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339
  • [6] Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Liang, Xinquan
    Deng, Lan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Jin, Hua
    Du, Xin
    Liu, Qifa
    BLOOD, 2022, 140 : 2025 - 2026
  • [7] THE USE OF VENETOCLAX WITH HYPOMETHYLATING AGENTS (HMAS) FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN A REAL-LIFE SETTING: THE BOLOGNA EXPERIENCE
    Nanni, J.
    Cristiano, G.
    Marconi, G.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Baldini, L.
    Testoni, N.
    Baldazzi, C.
    Paolini, S.
    Cavo, M.
    Papayannidis, C.
    Curti, A.
    HAEMATOLOGICA, 2019, 104 : 137 - 137
  • [8] Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
    Zainaldin, Carl
    Arora, Sankalp
    Bathini, Sri
    Pandya, Vishruti
    Bae, Sejong
    Gupta, Udita
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly Nicole
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna E.
    Di Stasi, Antonio
    Vachhani, Pankit
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18808 - E18808
  • [9] Combination of Venetoclax and Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: Single-Center Clinical Experience
    Secilmis, Sema
    Bozan, Ersin
    Darcin, Tahir
    Yaman, Samet
    Yigenoglu, Tugcenur
    Ulu, Bahar Uncu
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Yildiz, Jale
    Baysal, Nuran Ahu
    Iskender, Dicle
    Cakar, Merih Kizil
    Sinan, Dal Mehmet
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S192 - S193
  • [10] Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting
    Nanni, Jacopo
    Papayannidis, Cristina
    Cristiano, Gianluca
    Marconi, Giovanni
    Sartor, Chiara
    Parisi, Sarah
    Ottaviani, Emanuela
    Baldini, Lorenza
    Testoni, Nicoletta
    Baldazzi, Carmen
    Ricci, Paolo
    Bezzi, Chiara Di Giovanni
    Abd-alatif, Rania
    Paolini, Stefania
    Cavo, Michele
    Curti, Antonio
    BLOOD, 2020, 136
12345